Friday, September 9, 2022

Astellas' Pompe disease gene therapy placed on hold by FDA - Fierce Biotech

The FDA has slammed the breaks on a phase 1/2 study of the Japanese pharma's Pompe disease gene therapy to investigate a report of nerve damage.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

2 muggers captured by RU students on campus - UNB

Rayhanul Ferdous, a student of Genetic Engineering and Biotechnology department who had his phone stolen told UNB: “I was walking on the eas...